170 related articles for article (PubMed ID: 32278634)
21. The novel phytocomponent asiaticoside-D isolated from Centella asiatica exhibits monoamine oxidase-B inhibiting potential in the rotenone degenerated cerebral ganglions of Lumbricus terrestris.
Subaraja M; Vanisree AJ
Phytomedicine; 2019 May; 58():152833. PubMed ID: 30903943
[TBL] [Abstract][Full Text] [Related]
22. The neurobehavioral changes induced by bilateral rotenone lesion in medial forebrain bundle of rats are reversed by L-DOPA.
Alam M; Mayerhofer A; Schmidt WJ
Behav Brain Res; 2004 May; 151(1-2):117-24. PubMed ID: 15084427
[TBL] [Abstract][Full Text] [Related]
23. Protective Effect of (-)Epigallocatechin-3-gallate on Rotenone-Induced Parkinsonism-like Symptoms in Rats.
Tseng HC; Wang MH; Chang KC; Soung HS; Fang CH; Lin YW; Li KY; Yang CC; Tsai CC
Neurotox Res; 2020 Mar; 37(3):669-682. PubMed ID: 31811588
[TBL] [Abstract][Full Text] [Related]
24. Colchicine protects dopaminergic neurons in a rat model of Parkinson's disease.
Salama M; Ellaithy A; Helmy B; El-Gamal M; Tantawy D; Mohamed M; Sheashaa H; Sobh M; Arias-Carrión O
CNS Neurol Disord Drug Targets; 2012 Nov; 11(7):836-43. PubMed ID: 23198691
[TBL] [Abstract][Full Text] [Related]
25. Neuroprotection by Paeoniflorin in the MPTP mouse model of Parkinson's disease.
Zheng M; Liu C; Fan Y; Yan P; Shi D; Zhang Y
Neuropharmacology; 2017 Apr; 116():412-420. PubMed ID: 28093210
[TBL] [Abstract][Full Text] [Related]
26. Ropinirole versus L-DOPA effects on striatal opioid peptide precursors in a rodent model of Parkinson's disease: implications for dyskinesia.
Ravenscroft P; Chalon S; Brotchie JM; Crossman AR
Exp Neurol; 2004 Jan; 185(1):36-46. PubMed ID: 14697317
[TBL] [Abstract][Full Text] [Related]
27. Cyperi Rhizoma inhibits the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced reduction in nigrostriatal dopaminergenic neurons in estrogen-deprived mice.
Kim HG; Hong J; Huh Y; Park C; Hwang DS; Choi JH; Oh MS
J Ethnopharmacol; 2013 Jun; 148(1):322-8. PubMed ID: 23639362
[TBL] [Abstract][Full Text] [Related]
28. Imipramine and amitriptyline ameliorate the rotenone model of Parkinson's disease in rats.
Kandil EA; Abdelkader NF; El-Sayeh BM; Saleh S
Neuroscience; 2016 Sep; 332():26-37. PubMed ID: 27365173
[TBL] [Abstract][Full Text] [Related]
29. Chondroitinase ABC reduces dopaminergic nigral cell death and striatal terminal loss in a 6-hydroxydopamine partial lesion mouse model of Parkinson's disease.
Fletcher EJR; Moon LDF; Duty S
BMC Neurosci; 2019 Dec; 20(1):61. PubMed ID: 31862005
[TBL] [Abstract][Full Text] [Related]
30. Ibuprofen or piroxicam protects nigral neurons and delays the development of l-dopa induced dyskinesia in rats with experimental Parkinsonism: Influence on angiogenesis.
Teema AM; Zaitone SA; Moustafa YM
Neuropharmacology; 2016 Aug; 107():432-450. PubMed ID: 27016022
[TBL] [Abstract][Full Text] [Related]
31. Cordycepin Exerts Neuroprotective Effects via an Anti-Apoptotic Mechanism based on the Mitochondrial Pathway in a Rotenone-Induced Parkinsonism Rat Model.
Jiang X; Tang P-C ; Chen Q; Zhang X; Fan Y-Y ; Yu BC; Gu X-X ; Sun Y; Ge X-Q ; Zhang X-L
CNS Neurol Disord Drug Targets; 2019; 18(8):609-620. PubMed ID: 31486758
[TBL] [Abstract][Full Text] [Related]
32. Edaravone guards dopamine neurons in a rotenone model for Parkinson's disease.
Xiong N; Xiong J; Khare G; Chen C; Huang J; Zhao Y; Zhang Z; Qiao X; Feng Y; Reesaul H; Zhang Y; Sun S; Lin Z; Wang T
PLoS One; 2011; 6(6):e20677. PubMed ID: 21677777
[TBL] [Abstract][Full Text] [Related]
33. L-DOPA reverses the hypokinetic behaviour and rigidity in rotenone-treated rats.
Alam M; Schmidt WJ
Behav Brain Res; 2004 Aug; 153(2):439-46. PubMed ID: 15265640
[TBL] [Abstract][Full Text] [Related]
34. L-deprenyl protects against rotenone-induced, oxidative stress-mediated dopaminergic neurodegeneration in rats.
Saravanan KS; Sindhu KM; Senthilkumar KS; Mohanakumar KP
Neurochem Int; 2006 Jul; 49(1):28-40. PubMed ID: 16490285
[TBL] [Abstract][Full Text] [Related]
35. Chronic exposure to rotenone, a dopaminergic toxin, results in peripheral neuropathy associated with dopaminergic damage.
Binienda ZK; Sarkar S; Mohammed-Saeed L; Gough B; Beaudoin MA; Ali SF; Paule MG; Imam SZ
Neurosci Lett; 2013 Apr; 541():233-7. PubMed ID: 23499956
[TBL] [Abstract][Full Text] [Related]
36. Neuroprotection of GLP-1/GIP receptor agonist via inhibition of mitochondrial stress by AKT/JNK pathway in a Parkinson's disease model.
Li T; Tu L; Gu R; Yang XL; Liu XJ; Zhang GP; Wang Q; Ren YP; Wang BJ; Tian JY
Life Sci; 2020 Sep; 256():117824. PubMed ID: 32445758
[TBL] [Abstract][Full Text] [Related]
37. VGLUT2 Is a Determinant of Dopamine Neuron Resilience in a Rotenone Model of Dopamine Neurodegeneration.
Buck SA; De Miranda BR; Logan RW; Fish KN; Greenamyre JT; Freyberg Z
J Neurosci; 2021 Jun; 41(22):4937-4947. PubMed ID: 33893220
[TBL] [Abstract][Full Text] [Related]
38. Melatonin treatment potentiates neurodegeneration in a rat rotenone Parkinson's disease model.
Tapias V; Cannon JR; Greenamyre JT
J Neurosci Res; 2010 Feb; 88(2):420-7. PubMed ID: 19681169
[TBL] [Abstract][Full Text] [Related]
39. Signature of Aberrantly Expressed microRNAs in the Striatum of Rotenone-Induced Parkinsonian Rats.
Horst CH; Schlemmer F; de Aguiar Montenegro N; Domingues ACM; Ferreira GG; da Silva Ribeiro CY; de Andrade RR; Del Bel Guimarães E; Titze-de-Almeida SS; Titze-de-Almeida R
Neurochem Res; 2018 Nov; 43(11):2132-2140. PubMed ID: 30267378
[TBL] [Abstract][Full Text] [Related]
40. Kolaviron protects against nigrostriatal degeneration and gut oxidative damage in a stereotaxic rotenone model of Parkinson's disease.
Farombi EO; Awogbindin IO; Olorunkalu PD; Ogbuewu E; Oyetunde BF; Agedah AE; Adeniyi PA
Psychopharmacology (Berl); 2020 Nov; 237(11):3225-3236. PubMed ID: 32651640
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
